Literature DB >> 32402487

Impact of Frailty on Mortality, Readmissions, and Resource Utilization After TAVI.

Aaqib H Malik1, Srikanth Yandrapalli2, Syed Zaid2, Suchith Shetty3, Ammar Athar4, Rahul Gupta4, Wilbert S Aronow2, Joshua B Goldberg5, Martin B Cohen2, Hasan Ahmad2, Steven L Lansman5, Gilbert H L Tang6.   

Abstract

With aging population and preponderance of severe aortic stenosis occurring in elderly patients, the number of transcatheter aortic valve implantations (TAVI) performed in the elderly are growing. Frailty is common in the elderly and is known to be associated with worse outcomes. We aimed to evaluate the impact of frailty on hospital readmissions rates after TAVI. We used the 2016 Nationwide Readmission Database and categorized patients who underwent TAVI low, intermediate, and high frailty status. The primary outcome was 6-months readmission rates across the 3 frailty categories. Secondary outcomes included causes of readmissions, in-hospital mortality and cost of care. STATA 16.0 was used for survey-specific statistical tests. Of 20,504 patients who underwent TAVI, 58.9% were low-, 39.6% were intermediate-, and 1.5% were in the high-frailty group. Overall in-hospital mortality was 1.9% (n = 396), and was 0.6%, 3.3%, and 16.8% (p <0.01) with increasing frailty. Of the 20,108 patients who survived to discharge, 6,427 (32%) patients were readmitted within 6-months after TAVI. Readmission rates increased across the categories from 27.9% in low, 37.6% in intermediate and 51.1% in high frailty group (p <0.01). While cardiac causes (mostly heart failure) were the predominant readmission etiologies across frailty categories (low: 51.2%, intermediate: 34.1%, high: 27.2%), rates of infectious and injury-related readmissions increased (low: 11%, intermediate: 30%, high: 45%). Mortality during readmissions also worsened from 0.8%, 5.3%, and 8.5% (p <0.01). Over 40% of patients undergoing TAVI were of intermediate-high frailty. In conclusion, an increasing frailty was associated with significantly worse postprocedure mortality, readmissions, and related mortality.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32402487     DOI: 10.1016/j.amjcard.2020.03.047

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Measurement and prognosis of frail patients undergoing transcatheter aortic valve implantation: a systematic review and meta-analysis.

Authors:  Zhe Li; Emily Dawson; Jessica Moodie; Janet Martin; Rodrigo Bagur; Davy Cheng; Bob Kiaii; Adam Hashi; Ran Bi; Michelle Yeschin; Ava John-Baptiste
Journal:  BMJ Open       Date:  2021-03-04       Impact factor: 2.692

2.  The use of linked routine data to optimise calculation of the Hospital Frailty Risk Score on the basis of previous hospital admissions: a retrospective observational cohort study.

Authors:  Andrew Street; Laia Maynou; Thomas Gilbert; Tony Stone; Suzanne Mason; Simon Conroy
Journal:  Lancet Healthy Longev       Date:  2021-03

3.  Low Circulating Musclin is Associated With Adverse Prognosis in Patients Undergoing Transcatheter Aortic Valve Implantation at Low-Intermediate Risk.

Authors:  Badder Kattih; Daniel C Carstens; Felicitas Boeckling; Tina Rasper; Graziella Pergola; Stefanie Dimmeler; Mariuca Vasa-Nicotera; Andreas M Zeiher; Silvia Mas-Peiro
Journal:  J Am Heart Assoc       Date:  2022-03-01       Impact factor: 6.106

Review 4.  Risk Factors for Hospital Readmission Post-Transcatheter Aortic Valve Implantation in the Contemporary Era: A Systematic Review.

Authors:  Raumil V Patel; Mithunan Ravindran; Ragavie Manoragavan; Abi Sriharan; Harindra C Wijeysundera
Journal:  CJC Open       Date:  2022-06-06

5.  Clinical outcomes and cumulative healthcare costs of TAVR vs. SAVR in Asia.

Authors:  Elise Chia-Hui Tan; Yung-Tsai Lee; Yu Chen Kuo; Tien-Ping Tsao; Kuo-Chen Lee; Ming-Chon Hsiung; Jeng Wei; Kuan-Chia Lin; Wei-Hsian Yin
Journal:  Front Cardiovasc Med       Date:  2022-09-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.